WINTON GROUP Ltd Buys 9,432 Shares of biote Corp. (NASDAQ:BTMD)

WINTON GROUP Ltd raised its position in biote Corp. (NASDAQ:BTMD) by 13.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 77,572 shares of the company’s stock after buying an additional 9,432 shares during the quarter. WINTON GROUP Ltd’s holdings in biote were worth $479,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Commonwealth Equity Services LLC bought a new stake in shares of biote during the fourth quarter worth approximately $68,000. Intech Investment Management LLC bought a new stake in shares of biote during the 4th quarter valued at $71,000. SG Americas Securities LLC acquired a new position in shares of biote in the 4th quarter valued at $76,000. Thompson Davis & CO. Inc. bought a new position in shares of biote in the 4th quarter worth $77,000. Finally, MetLife Investment Management LLC grew its stake in shares of biote by 129.1% during the third quarter. MetLife Investment Management LLC now owns 16,582 shares of the company’s stock worth $93,000 after purchasing an additional 9,343 shares during the period. 21.68% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Craig Hallum cut their target price on biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th.

Insider Activity at biote

In other biote news, major shareholder Guines Llc bought 750,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was purchased at an average cost of $3.22 per share, with a total value of $2,415,000.00. Following the completion of the purchase, the insider now owns 3,820,938 shares in the company, valued at approximately $12,303,420.36. The trade was a 24.42 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Stephen Mark Cone purchased 38,104 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were acquired at an average cost of $3.88 per share, for a total transaction of $147,843.52. Following the transaction, the director now owns 160,829 shares of the company’s stock, valued at $624,016.52. This trade represents a 31.05 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 788,204 shares of company stock worth $2,563,218 in the last quarter. Corporate insiders own 13.90% of the company’s stock.

biote Stock Performance

Shares of NASDAQ BTMD opened at $3.39 on Monday. The firm has a 50 day moving average price of $4.58 and a 200 day moving average price of $5.39. The stock has a market cap of $185.47 million, a P/E ratio of 13.04 and a beta of 1.07. biote Corp. has a 52-week low of $3.04 and a 52-week high of $8.44.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.